Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
A Nature Medicine article presents a pooled analysis of phase 1 and 1/2 trials of a TIL cell therapy engineered with regulatable membrane-bound IL-15, studied in patients with immune checkpoint inhibitor-resistant advanced melanoma. Specific results are not provided in the available material.
AI summary · generated only from source feed metadata; consult originalSource published
Published here
views1
Original source
Nature Medicine
Media report · consult original reporting
Read the original ↗https://www.nature.com/articles/s41591-026-04743-6Original headline
Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
AI bilingual edit · consult originalHeadlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.